Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Lucatumumab (HCD122) (formerly CHIR-12.12)
print preview
bookmark
share with colleague
General Information
Company
Xoma Corp.
Description
Human mAb against CD40
Molecular Target
CD40
Mechanism of Action
Antibody
Latest Stage of Development
Phase I/II
Indication
Lymphoma
Partner
Novartis AG
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy